For Graves’ patients, a destination for compassion and innovation

Graves’ eye disease, also called thyroid eye disease or TED, is an exceptionally uncomfortable and disfiguring condition that can also be debilitating for many patients. The U-M Kellogg Eye Center is an international destination center for the multidisciplinary treatment of TED and related autoimmune disorders, and for groundbreaking research to advance our understanding of the development and treatment of these diseases.

Because TED strikes each individual differently, patients treated at Kellogg benefit from personalized care planning and coordinated care with U-M specialists in other related disciplines. Our team of specialists includes orbital surgeons, strabismus surgeons, orthoptists and neuro-ophthalmologists, all experienced in the unique needs of TED patients. Working with each patient to understand his or her goals for rehabilitation, we develop a coordinated treatment plan for each patient.

Pioneering minimally-invasive surgical options

Some of the most significant advances in care available at Kellogg are minimally invasive surgical options, including procedures performed by Raymond Douglas, M.D., Ph.D.  A specialist in Graves' eye disease and renowned orbital, facial plastic and reconstructive surgeon, Dr. Douglas has modified standard surgical practice for reconstruction in TED, resulting in today’s patients requiring far fewer and less invasive surgeries, faster recovery and improved appearance and function.

Fellow oculoplastic surgeon Alon Kahana, M.D., Ph.D., has introduced a new “stereotactic” 3-D navigation system to the Eye Center that allows surgeons to perform orbital decompression surgery with smaller incisions for a faster and safer result. “Given the proximity of the eye, brain and other vital structures, it appears that stereotactic deep orbital surgery could become the new standard of care,” says Kahana.

RV 001: an investigational drug trial for TED

Patients diagnosed with TED may be eligible to participate in a study on the safety and effectiveness of an investigational drug called RV 001. The study lasts approximately 18 months and includes up to 19 clinic visits. To find out more, visit http://www.kellogg.umich.edu/research/open_clinicaltrials.html

TED Care funds surgery, support

In November, 2014 a generous and grateful TED patient made an anonymous $1.5 million gift establishing a fund to help fellow sufferers face the physical, emotional and financial challenges of the disease. The fund, called TED Care, provides financial support to offset expenses for surgery or travel to the Kellogg Eye Center. “In making this exceptional gift,” notes Dr. Douglas, ”our donor expressed his gratitude for our care and attention to his needs. He wants to be sure that every patient experiences the same individualized care.”

To refer a patient, contact the Thyroid Eye Disease Clinic at 734-764-5106 or call M-LINE at 800-962-3555.
To learn more about TED Care, call 734-615-1472 or email UMThyroidEyeDisease@med.umich.edu.